1-3 of 3
Camille Granvil, PhD
Close
Sort by
Journal Articles

Pharmacodynamic Study of Copanlisib in Patients with Non-Hodgkin's Lymphoma and Advanced Solid Tumors: Confirmation of on-Target PI3K Inhibitory Activity

Franck Morschhauser, MD PhD, Ahmad Awada, MD PhD, Jean-Pascal Machiels, MD PhD, Gilles Andre Salles, MD PhD, Sylvie Rottey, MD PhD, Simon Rule, MD, David Cunningham, MD FRCP, Frederic Peyrade, MD, Christophe Fruchart, MD, Hendrik-Tobias Arkenau, MD PhD, Isabelle Genvresse, MD, Li Liu, PhD, Christoph Kneip, PhD, Carol Pena, PhD, Joachim Grevel, PhD, Jun Zhang, PhD, Galia Cisternas, PhD, Susanne Reschke, MSc, Camille Granvil, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1256.
https://doi.org/10.1182/blood.V130.Suppl_1.1256.1256
Published: 2017
Journal Articles

Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.

Dong-Wook Kim, MD, PhD, Camille Granvil, PhD, Eren Demirhan, John Reynolds, Yu Jin, MSc, Yanfeng Wang, PhD, Michele Baccarani, MD, Jorge Cortes-Franco, MD, Brian J. Druker, MD, Timothy P. Hughes, MD, MBBS, François Guilhot, MD
Journal: Blood
Blood (2009) 114 (22): 1127.
https://doi.org/10.1182/blood.V114.22.1127.1127
Published: 2009
Journal Articles

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

Richard A. Larson, MD, Yen Lin Chia, PhD, Camille Granvil, PhD, François Guilhot, MD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Michele Baccarani, MD, Timothy P. Hughes, MD, MBBS, Jerry R. Nedelman, PhD, Yanfeng Wang, PhD
Journal: Blood
Blood (2009) 114 (22): 2213.
https://doi.org/10.1182/blood.V114.22.2213.2213
Published: 2009